CORRECTING and REPLACING Innovation and The Supreme Court: Two Cases to Watch

Bowman v. Monsanto Arguments Begin February 19th

ADVISORY...
CORRECTION...by Biotechnology Industry Organization

--()--In WHERE section of release dated Feb. 11, 2013, Conference Code PIN should read: 5246534849 (sted 9649).

The corrected release reads:

INNOVATION AND THE SUPREME COURT: TWO CASES TO WATCH

Bowman v. Monsanto Arguments Begin February 19th

Biotechnology Industry Organization:

   

WHAT:

An inside look at two cases facing the Supreme Court of the United States: Bowman v. Monsanto and Molecular Pathology v. Myriad Genetics.

 

 

This call will provide you with experts who will explain the broad reaching impacts and implications of these two very different cases, each of which present distinct questions of patent law that could affect the future of innovation in biotechnology in different ways. In Bowman v. Monsanto, the Supreme Court will address whether patent law prevents the reproduction of patented products -like genetically engineered seeds, live vaccines, synthetic cell lines, nucleic acid preparations, and other promising new scientific products-that, as a technological matter, can be easily reproduced at exponential rates. In Association for Molecular Pathology v. Myriad Genetics, the Court will address, as a threshold matter of patent law, whether laboratory preparations of isolated DNA molecules that were derived from natural sources can be eligible for patenting.

 
WHO:

--

Jim Greenwood, President & CEO, BIO

--

Hans Sauer, Deputy General Counsel, Intellectual Property, BIO

--

Gary Baise, Olsson Frank Weeda Terman Matz PC; Counsel of Record, American Soybean Association

--

Scott McBride, McAndrews, Held & Malloy; Counsel of record for the Wisconsin Alumni Research Foundation

--

Christopher Holman, University of Missouri – Kansas City School of Law

 

WHEN:

Thursday, February 14, 2013, 11:00 a.m. - 12:30 p.m. EDT

11:00-11:45 – Part I: Bowman v. Monsanto – discussion and Q&A
11:45-12:30 – Part II: Molecular Pathology v. Myriad Genetics – discussion and Q&A
 
WHERE:

Conference Call

Dial-In #: 1-866-393-9713

Conference Code PIN: 5246534849

 

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.

Contacts

Biotechnology Industry Organization
George Goodno, 202-962-9660
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech

Release Summary

An inside look at two cases facing the Supreme Court of the United States: Bowman v. Monsanto (arguments begin February 19th) and Molecular Pathology v. Myriad Genetics.

Sharing

Contacts

Biotechnology Industry Organization
George Goodno, 202-962-9660
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech